On April 22, 2024, ImmunityBio's Anktiva (N-803) plus BCG got FDA approval for BCG-unresponsive NMIBC with CIS, with/without papillary tumors.

4.15-4.21 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

4.8-4.14 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

The article presents the clinical trial outcomes that failed globally in March.

The article presents the clinical trial outcomes that failed globally in February.

Up to now, at the AACR meeting, updates on the clinical progress of several ADC drugs have been presented, involving targets such as HER2, BCMA, CD123, FRα, CCR7, Axl, etc.

The failure of clinical trials can stem from multiple factors. One study suggests that 90% of drug development clinical failures may be attributed to four reasons: lack of clinical efficacy (40%-50%), uncontrollable toxicity (30%), poor pharmacokinetic properties (10%-15%), and absence of commercial demand or poor strategic planning (10%).

4.1-4.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Curated Selection of the Latest Developments in the Field of New Drug Research and Development: A Quick Overview of Progress in New Drug R&D, Pharmaceutical Deals, and Cutting-Edge Technologies from This Week.

This article introduces the new drugs related to GPCR that were approved by the FDA in 2023.